Lexicon Pharmaceuticals Says Post Hoc Analysis Of Phase 3 SOLOIST-WHF Trial Shows Sotagliflozin Reduced Cardiovascular Deaths, Heart Failure Events Regardless Of Baseline Systolic Blood Pressure, Without Increase In Hypotension Or Acute Kidney Injury
Share
Why It Matters
Lexicon found that their heart medicine worked well for many patients, showing it helped prevent serious heart problems without causing common side effects. When a company's medicine shows it helps lots of different patients safely, people often feel more confident about whether it could be useful.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.